Skip to content
value.today
Impel Neuropharma Inc. logo

Impel Neuropharma Inc.

Total raised
$31 M
5 rounds on record
Latest round
$22 M
Nov 2016
First round on record
Nov 2013
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Impel Neuropharma Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2016$22 MNo. 5$10 to $50 million

Impel Neuropharma Inc.: Raise no. 5, Nov 2016

Investors in this round

10 investors had bought by the notice of Dec 1, 2016: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 19 investors are named for Impel Neuropharma Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$22 M of $37 M offered; $15 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,000,000
Finders' fees
$2,498
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John D. Hoekman · Executive Officer, Director
  • Aaron D. Royston · Director
  • Jim D. Young · Director
  • Mahendra D. Shah · Director
  • Stewart D. Parker · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Kevin Cable (CRD 480071) · broker-dealer Cascadia Capital, LLC (CRD 101020) · Seattle, WashingtonSold in CA, CT, DC, FL, GA, IL, IN, MA, MD, MI, MN, MO, NJ, NY, OH, PA, WA

Signed by John Hoekman, President and CEO. Source: SEC Form D, newest notice filed Dec 1, 2016. Read the notice at the SEC.

equitySEC
Jul 2016$1 MNo. 4Under $2 million

Impel Neuropharma Inc.: Raise no. 4, Jul 2016

Investors in this round

4 investors had bought by the notice of Aug 29, 2016: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 19 investors are named for Impel Neuropharma Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $2 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John D. Hoekman · Executive Officer, Director
  • Stewart D. Parker · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Hoekman, President and CEO. Source: SEC Form D, newest notice filed Aug 29, 2016. Read the notice at the SEC.

debt, optionsSEC
Sep 2015$4 MNo. 3$2 to $10 million

Impel Neuropharma Inc.: Raise no. 3, Sep 2015

Investors in this round

1 investor had bought by the notice of Sep 18, 2015: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 19 investors are named for Impel Neuropharma Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $12 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John D. Hoekman · Executive Officer, Director
  • Michael P. Hite · Executive Officer, Director
  • Stewart D. Parker · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael P. Hite, President and CEO. Source: SEC Form D, newest notice filed Sep 18, 2015. Read the notice at the SEC.

equity, optionsSEC
Aug 2015$1 MNo. 2Under $2 million

Impel Neuropharma Inc.: Raise no. 2, Aug 2015

Investors in this round

21 investors had bought by the notice of Sep 14, 2015: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 19 investors are named for Impel Neuropharma Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John D. Hoekman · Executive Officer, Director
  • Michael P. Hite · Executive Officer, Director
  • Stewart D. Parker · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The above reflects the conversion of debt into equity.”

Signed by Michael P. Hite, President and CEO. Source: SEC Form D, newest notice filed Sep 14, 2015. Read the notice at the SEC.

equitySEC
Nov 2013$3 MNo. 1$2 to $10 million

Impel Neuropharma Inc.: Raise no. 1, Nov 2013

Investors in this round

19 investors had bought by the notice of Nov 27, 2013: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 19 investors are named for Impel Neuropharma Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $4 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John D. Hoekman · Executive Officer, Director
  • Michael P. Hite · Executive Officer, Director
  • Rodney D. Ho · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael P. Hite, President and CEO. Source: SEC Form D, newest notice filed Nov 27, 2013. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Impel Neuropharma Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2016).

    SEC Form D · Dec 2016

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Dec 2016

That is all the official record says: Impel Neuropharma Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

In its own words

How the company describes itself to search engines on its website, word for word.

“Impel Pharmaceuticals specializes in Precision Olfactory Delivery (POD) nasal devices for Alzheimer's, migraine, and other central nervous system diseases.”

Source: The company's website · as of Nov 15, 2026

Products and services#

No products or services on record: its website does not describe any in structured form (a page that declares itself a product or service), and Wikidata lists none.

Investors#

19 named in official filings. Open an investor to see everything it has backed.

Investors in Impel Neuropharma Inc.
InvestorKindAmountRoundRoleSource
5AM Partners V, LLCFund or asset managernot statednot statedHeld Series C-1, C-2, C-3 and D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
5AM Ventures V, L.P.Venture capitalnot statednot statedHeld Series C-1, C-2, C-3 and D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
H. Stewart ParkerPersonnot statednot statedHeld Series A-2 and C-1 preferred stock, director (Form 3, 2021)SEC Form 3
John HoekmanPersonnot statednot statedHeld Series A-2 preferred stock (Form 3, 2021)SEC Form 3
KKR Associates HCSG L.P.Fund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
KKR & Co. L.P.Fund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
KKR Fund Holdings L.P.Fund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
KKR Group Holdings Corp.Companynot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
KKR Hcsg GP LLCOthernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
KKR Healthcare Strategic Growth Fund L.P.Fund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
KKR Iris Investors LLCFund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
KKR Management LLCFund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Norwest Venture Partners XIV, LPVenture capitalnot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
venBio Global Strategic Fund II L.P.Fund or asset managernot statednot statedHeld Series C-1, C-2, C-3 and D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
venBio Global Strategic GP II, L.P.Fund or asset managernot statednot statedHeld Series C-1, C-2, C-3 and D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
venBio Global Strategic GP II, Ltd.Companynot statednot statedHeld Series C-1, C-2, C-3 and D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Vivo Capital Fund VIII, L.P.Fund or asset managernot statednot statedHeld Series C-1, C-2, C-3 and D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Vivo Capital Surplus Fund VIII, L.P.Fund or asset managernot statednot statedHeld Series C-1, C-2, C-3 and D preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Vivo Capital VIII, LLCFund or asset managernot statednot statedHeld Series C-1, C-2, C-3 and D preferred stock, 10% owner (Form 3, 2021)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 21 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Impel Neuropharma Inc.
NameRoleNamed in
John D. HoekmanExecutive officerDec 2016
Michael P. HiteExecutive officerSep 2015
Aaron D. RoystonDirectorDec 2016
Jim D. YoungDirectorDec 2016
John D. HoekmanDirectorDec 2016
Mahendra D. ShahDirectorDec 2016
Stewart D. ParkerDirectorDec 2016
Michael P. HiteDirectorSep 2015
Rodney D. HoDirectorNov 2013

About

Company in Seattle, United States.